Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02553603 · ClinicalTrials.gov registry record · Phase 1
The Effect of Growth Hormone Releasing Hormone on Cognitive Function in Individuals With Mild Cognitive Impairment
A Phase 1 study, sponsored by The University of Texas Medical Branch, Galveston.
- Completed
- Registry status
- Phase 1
- Development phase
- 22
- Enrollment target
NCT02553603 is a Phase 1 study that has completed, run by The University of Texas Medical Branch, Galveston. The registered enrollment target is 22 participants.
The verdict
NCT02553603, a Phase 1 study, has completed, sponsored by The University of Texas Medical Branch, Galveston.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 22 participants
- Enrollment target
Study Summary
This study is examining the effects of growth hormone releasing hormone (GHRH) on mild cognitive impairment (MCI). GHRH will be given at a dose of 1mg/day for 10 weeks to subjects with MCI as well as healthy controls.
Interventions
- DRUG Growth Hormone Releasing Hormone (GHRH)
- DRUG Placebo Growth Hormone Releasing Hormone
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 22 participants |
| Start Date | 2017-07-18 |
| Est. Completion | 2019-01-17 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02553603
The ClinicalTrials.gov registry entry for NCT02553603 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 22 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is The University of Texas Medical Branch, Galveston, which has 203 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Growth Hormone Releasing Hormone (GHRH) is the first listed.
NCT02553603 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02553603 about?
NCT02553603 is a clinical study titled "The Effect of Growth Hormone Releasing Hormone on Cognitive Function in Individuals With Mild Cognitive Impairment". This study is examining the effects of growth hormone releasing hormone (GHRH) on mild cognitive impairment (MCI). GHRH will be given at a dose of 1mg/day for 10 weeks to subjects with MCI as well as healthy controls.
What is the current status of trial NCT02553603?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 22 participants. The study started on 2017-07-18. Estimated completion is 2019-01-17.
What interventions are being tested in trial NCT02553603?
The interventions under investigation include: Growth Hormone Releasing Hormone (GHRH) (DRUG), Placebo Growth Hormone Releasing Hormone (DRUG).
Who is sponsoring clinical trial NCT02553603?
This trial is sponsored by The University of Texas Medical Branch, Galveston, which has 203 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.